3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
9
Phase 1/2
3
Phase 3
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
9
Genitourinary
3
Breast
2
Tumor-Agnostic
1
Thoracic
1
Gastrointestinal
1
CNS
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Ovarian Neoplasms
1
Interventions
Cyclophosphamide
171
Docetaxel
163
Paclitaxel
160
Trastuzumab
151
Capecitabine
130
Tamoxifen
119
Letrozole
105
Epirubicin
93
Doxorubicin
83
Anastrozole
83
exemestane
77
Fulvestrant
75
Carboplatin
64
Fluorouracil
63
Radiotherapy
61
pertuzumab
59
Gemcitabine
55
Vinorelbine
43
Goserelin
39
eribulin
36
130-nm albumin-bound paclitaxel
36
palbociclib
32
Bevacizumab
32
ribociclib
30
Zoledronic Acid
29
Lapatinib
29
Methotrexate
28
Drug Therapy
28
Chemotherapy, Adjuvant
28
Ado-Trastuzumab Emtansine
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
niraparib
×
Breast
×
Clear all
NCT04915755
2025-07-16
ZEST
GlaxoSmithKline
Phase 3
Active not recruiting
40 enrolled
13 charts
NCT01905592
2022-11-15
BRAVO
Tesaro, Inc.
Phase 3
Terminated
216 enrolled
19 charts